LIDDS has today launched a newly designed website that will better reflect the ongoing company activities and the NanoZolid® project development pipeline. At the same time the web address is changed to liddspharma.com
Welcome to the website!
For more information, please contact:
Monica Wallter, CEO, +46 (0)737 07 09 22, e-mail: monica.wallter@liddspharma.com
Bengt Norvik, CFO, +46 (0)730 74 68 00, e-mail: bengt.norvik@liddspharma.com
About Lidds
LIDDS AB (publ) develops effective medications for cancer and other diseases with the patented NanoZolid® technology. NanoZolid® releases the medication locally and efficiently, which means significantly fewer side effects and treatments compared with systemic treatment. NanoZolid® technology allows for the controlled, long-term and adjusted release of the medication for up to six months. NanoZolid® can be combined with both large and small pharmaceutical molecules, such as antibodies. The company's most advance project is the prostate cancer product Liproca® Depot, which contains 2-hydroxyflutamide, which confirms that the technology has a documented clinical effect. The prostate cancer project is currently in Phase IIb. Industrial-scale production is taking place in collaboration with Recipharm. LIDDS has active development projects where NanoZolid® is combined with antiandrogens, cytostatics and immunoactive agents. LIDDS shares are listed on Nasdaq, First North. Redeye AB is a certified adviser to LIDDS AB. For more information, go to liddspharma.com.
—
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LIDDS AB via Globenewswire